{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:54:59Z","timestamp":1793660099437,"version":"4.5.1"},"reference-count":55,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>X-linked hypophosphatemia (XLH) is a progressive disease in which excess fibroblast growth factor 23 (FGF23) causes renal phosphate wasting, leading to hypophosphatemia. Consequences in adults include osteomalacia, fractures, pseudofractures, joint dysfunction, pain, and impaired mobility. Treatments for XLH are the anti-FGF23 antibody burosumab and active forms of vitamin D alone or in combination with oral phosphate (Pi\/D). Randomized studies comparing burosumab with Pi\/D in adults with XLH are lacking. We present a 3-yr follow-up analysis evaluating real-world effectiveness of burosumab vs Pi\/D based on biochemistry and standardized symptom assessments (Western Ontario and McMaster Universities Osteoarthritis Index [WOMAC]) using data from the XLH Disease Monitoring Program (DMP; NCT03651505), a prospective, Americas-based study. Adults with XLH initiated burosumab between baseline and the year 1 visit (N\u2009=\u200954) or reported being on Pi\/D therapy at enrollment (N\u2009=\u200955) were included. After adjusting for baseline differences using inverse probability of treatment weighting, the data showed a significantly higher mean (SD) change from baseline in serum phosphate with burosumab vs Pi\/D (year 1: 0.8 [0.8] vs 0.1 [0.7] mg\/dL; year 3: 0.6 [0.8] vs 0.1 [0.7] mg\/dL, both p\u2009&amp;lt;\u2009.001). A higher proportion of burosumab vs Pi\/D participants achieved serum phosphate levels above the lower limit of normal (2.5\u00a0mg\/dL; year 1: 70.5% vs 18.8%; year 3: 60.8% vs 25.0%, both p\u2009&amp;lt;\u2009.001). At year 1, changes from baseline in WOMAC pain (\u22126.3 [27.7] vs 2.1 [22.4], p\u2009=\u2009.055), physical function (\u22126.4 [19.1] vs 0.1 [29.0], p\u2009=\u2009.122), and stiffness (\u221211.1 [32.1] vs \u22122.3 [33.7], p\u2009=\u2009.073) were not statistically significant between cohorts, but were significant at year 3 (pain: \u22129.8 [22.6] vs 3.3 [24.1], p\u2009&amp;lt;\u2009.001; physical function: \u221210.0 [25.7] vs 3.3 [24.7], p\u2009=\u2009.001; stiffness: \u221215.2 [29.5] vs \u22123.7 [31.4], p\u2009=\u2009.016). In this real-world analysis of adults with XLH over a 3-yr follow-up, burosumab treatment was associated with improved serum phosphate and patient-reported outcomes vs Pi\/D.<\/jats:p>","DOI":"10.1093\/jbmr\/zjag136","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:54:49Z","timestamp":1790164489000},"source":"Crossref","is-referenced-by-count":1,"title":["Real-world effectiveness of burosumab versus oral phosphate and active vitamin D in adults with X-linked hypophosphatemia (XLH): a 3-year follow-up of the XLH Disease Monitoring Program"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4343-6723","authenticated-orcid":false,"given":"Steven W","family":"Ing","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism, The Ohio State University Wexner Medical Center , Columbus, OH 43210 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6917-5333","authenticated-orcid":false,"given":"Sasigarn A","family":"Bowden","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The Ohio State University , Columbus, OH 43205 ,","place":["United States"]},{"name":"Division of Pediatric Endocrinology, Nationwide Children's Hospital , Columbus, OH 43205 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9980-9138","authenticated-orcid":false,"given":"Kathryn M","family":"Dahir","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Diabetes, Program for Metabolic Bone Disorders at Vanderbilt Health , Nashville, TN 37232 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5936-3146","authenticated-orcid":false,"given":"Pablo","family":"Florenzano","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, School of Medicine, Pontificia Universidad Cat\u00f3lica de Chile , Santiago 8320165 ,","place":["Chile"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4712-8821","authenticated-orcid":false,"given":"Ingrid A","family":"Holm","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Harvard Medical School , Boston, MA 02115 ,","place":["United States"]},{"name":"Division of Genetics and Genomics and Division of Endocrinology, Boston Children\u2019s Hospital , Boston, MA 02115 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3604-303X","authenticated-orcid":false,"given":"Sarah","family":"Khan","sequence":"additional","affiliation":[{"name":"Bone Research and Education Center , Oakville, ON , L6M 4H8,","place":["Canada"]},{"name":"Trillium Health Partners , Mississauga, ON , L5A 4G1,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0036-7809","authenticated-orcid":false,"given":"Michael A","family":"Levine","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Diabetes, The Children's Hospital of Philadelphia , Philadelphia, PA 19104 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2750-2583","authenticated-orcid":false,"given":"Carolina A","family":"Moreira","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Endocrine Division (SEMPR), Federal University of Parana and Academic Research Center of Pro Renal Institution , Curitiba, PR 80440-020 ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8186-5967","authenticated-orcid":false,"given":"Laila","family":"Tabatabai","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Weill Cornell Medical College, Houston Methodist Hospital , Houston, TX 77030 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2868-2288","authenticated-orcid":false,"given":"Thomas J","family":"Weber","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Metabolism and Nutrition, Duke University Medical Center , Durham, NC 27710 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8184-8284","authenticated-orcid":false,"given":"Shubham","family":"Tewari","sequence":"additional","affiliation":[{"name":"KMK Consulting Inc. , Morristown, NJ 07960 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3938-0920","authenticated-orcid":false,"given":"Ben","family":"Johnson","sequence":"additional","affiliation":[{"name":"Kyowa Kirin International plc , Marlow , SL7 1HZ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0985-4550","authenticated-orcid":false,"given":"Marc","family":"Vincent","sequence":"additional","affiliation":[{"name":"Kyowa Kirin Inc. , Princeton, NJ 08540,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3182-3532","authenticated-orcid":false,"given":"Jaimin","family":"Patel","sequence":"additional","affiliation":[{"name":"Kyowa Kirin Inc. , Princeton, NJ 08540,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2296-3928","authenticated-orcid":false,"given":"Lak Nilusha","family":"Kotinkaduwa","sequence":"additional","affiliation":[{"name":"Kyowa Kirin Inc. , Princeton, NJ 08540,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0779-9720","authenticated-orcid":false,"given":"Zhiyi","family":"Li","sequence":"additional","affiliation":[{"name":"Kyowa Kirin Inc. , Princeton, NJ 08540,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1557-9185","authenticated-orcid":false,"given":"Leanne M","family":"Ward","sequence":"additional","affiliation":[{"name":"Division of Pediatric Endocrinology, Children's Hospital of Eastern Ontario, University of Ottawa , Ottawa, ON K1H 8L1 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7284-3467","authenticated-orcid":false,"given":"Erik A","family":"Imel","sequence":"additional","affiliation":[{"name":"Departments of Medicine and Pediatrics, Endocrinology, Indiana University School of Medicine , Indianapolis, IN 46202 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"on behalf of the DMP Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"issue":"8","key":"2026101614021659300_ref1","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1210\/clinem\/dgaf170","article-title":"X-linked hypophosphatemia management in adults: an International Working Group Clinical Practice Guideline","volume":"110","author":"Khan","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026101614021659300_ref2","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/s41581-024-00926-x","article-title":"Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia","volume":"21","author":"Haffner","year":"2025","journal-title":"Nat Rev Nephrol"},{"issue":"7","key":"2026101614021659300_ref3","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1002\/jbmr.340","article-title":"A clinician's guide to X-linked hypophosphatemia","volume":"26","author":"Carpenter","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"10","key":"2026101614021659300_ref4","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1007\/s00198-021-05997-1","article-title":"Burden of disease and clinical targets in adult patients with X-linked hypophosphatemia. A comprehensive review","volume":"32","author":"Giannini","year":"2021","journal-title":"Osteoporos Int"},{"issue":"3","key":"2026101614021659300_ref5","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1530\/EJE-08-0818","article-title":"Incidence and prevalence of nutritional and hereditary rickets in southern Denmark","volume":"160","author":"Beck-Nielsen","year":"2009","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"2026101614021659300_ref6","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1507\/endocrj.EJ15-0275","article-title":"Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment","volume":"62","author":"Endo","year":"2015","journal-title":"Endocr J"},{"issue":"3","key":"2026101614021659300_ref7","doi-asserted-by":"publisher","first-page":"e871","DOI":"10.1210\/clinem\/dgz203","article-title":"Prevalence and mortality of individuals with X-linked hypophosphatemia: a United Kingdom real-world data analysis","volume":"105","author":"Hawley","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026101614021659300_ref8","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1530\/EJE-15-0515","article-title":"Hereditary hypophosphatemia in Norway: a retrospective population-based study of genotypes, phenotypes, and treatment complications","volume":"174","author":"Rafaelsen","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"2026101614021659300_ref9","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4614-0887-1_4","article-title":"Evidence for FGF23 involvement in a bone-kidney axis regulating bone mineralization and systemic phosphate and vitamin D homeostasis","volume":"728","author":"Martin","journal-title":"Endocrine FGFs and Klothos. Advances in Experimental Medicine and Biology"},{"issue":"12","key":"2026101614021659300_ref10","doi-asserted-by":"publisher","first-page":"bvaa151","DOI":"10.1210\/jendso\/bvaa151","article-title":"X-linked hypophosphatemia: a new era in management","volume":"4","author":"Dahir","year":"2020","journal-title":"J Endocr Soc"},{"issue":"7","key":"2026101614021659300_ref11","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1007\/s11136-020-02465-x","article-title":"Exploring the burden of X-linked hypophosphatemia: a European multi-country qualitative study","volume":"29","author":"Lo","year":"2020","journal-title":"Qual Life Res"},{"issue":"1","key":"2026101614021659300_ref12","doi-asserted-by":"publisher","first-page":"6540026","DOI":"10.1155\/2024\/6540026","article-title":"Rare causes of musculoskeletal pain: thinking beyond common rheumatologic diseases","volume":"2024","author":"Charles","year":"2024","journal-title":"Case Rep Rheumatol"},{"key":"2026101614021659300_ref13","volume-title":"StatPearls [Internet]","author":"Chauhan","year":"2023"},{"key":"2026101614021659300_ref14","volume-title":"StatPearls [Internet]","author":"Wenker"},{"issue":"8","key":"2026101614021659300_ref15","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.3390\/ijms22083891","article-title":"Fibromyalgia: pathogenesis, mechanisms, diagnosis and treatment options update","volume":"22","author":"Siracusa","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"12","key":"2026101614021659300_ref16","doi-asserted-by":"publisher","first-page":"e1524","DOI":"10.1210\/clinem\/dgad383","article-title":"Development of spinal enthesopathies in adults with X-linked hypophosphatemia","volume":"108","author":"Herrou","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026101614021659300_ref17","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s40620-024-01962-3","article-title":"X-linked hypophosphatemia. Data from a Spanish adult population cohort","volume":"37","author":"L\u00f3pez-Romero","year":"2024","journal-title":"J Nephrol"},{"key":"2026101614021659300_ref18","doi-asserted-by":"publisher","first-page":"641543","DOI":"10.3389\/fendo.2021.641543","article-title":"Consensus recommendations for the diagnosis and management of X-linked hypophosphatemia in Belgium","volume":"12","author":"Laurent","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"2026101614021659300_ref19","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s40265-018-0905-7","article-title":"Burosumab: first global approval","volume":"78","author":"Lamb","year":"2018","journal-title":"Drugs."},{"issue":"10","key":"2026101614021659300_ref20","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1530\/EC-20-0291","article-title":"Clinical guidelines for burosumab in the treatment of XLH in children and adolescents: British paediatric and adolescent bone group recommendations","volume":"9","author":"Padidela","year":"2020","journal-title":"Endocr Connect"},{"issue":"8","key":"2026101614021659300_ref21","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1002\/jbmr.3475","article-title":"A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis","volume":"33","author":"Insogna","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2026101614021659300_ref22","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00223-019-00568-3","article-title":"Continued beneficial effects of burosumab in adults with X-linked hypophosphatemia: results from a 24-week treatment continuation period after a 24-week double-blind placebo-controlled period","volume":"105","author":"Portale","year":"2019","journal-title":"Calcif Tissue Int"},{"issue":"3","key":"2026101614021659300_ref23","doi-asserted-by":"publisher","first-page":"e001714","DOI":"10.1136\/rmdopen-2021-001714","article-title":"Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension","volume":"7","author":"Briot","year":"2021","journal-title":"RMD Open"},{"issue":"6","key":"2026101614021659300_ref24","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1210\/clinem\/dgae890","article-title":"Systematic review: efficacy of medical therapy on outcomes important to adult patients with X-linked hypophosphatemia","volume":"110","author":"Ali","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2026101614021659300_ref25","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1093\/jbmr\/zjaf063","article-title":"Real-world effectiveness of burosumab versus oral phosphate and active vitamin D in adults with X-linked hypophosphatemia","volume":"40","author":"Florenzano","year":"2025","journal-title":"J Bone Miner Res"},{"key":"2026101614021659300_ref26","author":"Labcorp. Parathyroid Hormone (PTH), Intact"},{"issue":"12","key":"2026101614021659300_ref27","first-page":"1833","article-title":"Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee","volume":"15","author":"Bellamy","year":"1988","journal-title":"J Rheumatol"},{"key":"2026101614021659300_ref28","author":"WOMAC Osteoarthritis Index. WOMAC 3.1 Index","year":"2021"},{"issue":"Suppl 11","key":"2026101614021659300_ref29","doi-asserted-by":"publisher","first-page":"S208","DOI":"10.1002\/acr.20632","article-title":"Measures of knee function: International Knee Documentation Committee (IKDC) Subjective Knee Evaluation Form, Knee Injury and Osteoarthritis Outcome Score (KOOS), Knee Injury and Osteoarthritis Outcome Score Physical Function Short Form (KOOS-PS), Knee Outcome Survey Activities of Daily Living Scale (KOS-ADL), Lysholm Knee Scoring Scale, Oxford Knee Score (OKS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Activity Rating Scale (ARS), and Tegner Activity Score (TAS)","volume":"63","author":"Collins","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"2026101614021659300_ref30","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5435\/00124635-201002000-00002","article-title":"Challenges with health-related quality of life assessment in arthroplasty patients: problems and solutions","volume":"18","author":"Singh","year":"2010","journal-title":"J Am Acad Orthop Surg"},{"issue":"5","key":"2026101614021659300_ref31","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1097\/CORR.0000000000002046","article-title":"How do PROMIS scores correspond to common physical abilities?","volume":"480","author":"Brodke","year":"2022","journal-title":"Clin Orthop Relat Res"},{"issue":"13-14","key":"2026101614021659300_ref32","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.5694\/mja2.12045","article-title":"The timed up and go test","volume":"210","author":"Browne","year":"2019","journal-title":"Med J Aust"},{"issue":"2","key":"2026101614021659300_ref33","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/j.1532-5415.1991.tb01616.x","article-title":"The timed \u201cUp & Go\u201d: a test of basic functional mobility for frail elderly persons","volume":"39","author":"Podsiadlo","year":"1991","journal-title":"J Am Geriatr Soc"},{"issue":"10","key":"2026101614021659300_ref34","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1097\/CORR.0000000000000444","article-title":"What is the minimum clinically important difference for the WOMAC index after TKA?","volume":"476","author":"Clement","year":"2018","journal-title":"Clin Orthop Relat Res"},{"issue":"4","key":"2026101614021659300_ref35","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/0197-2456(89)90005-6","article-title":"Measurement of health status. Ascertaining the minimal clinically important difference","volume":"10","author":"Jaeschke","year":"1989","journal-title":"Control Clin Trials"},{"issue":"Supplement 3","key":"2026101614021659300_ref36","first-page":"S870","article-title":"Confirmatory psychometric validation of the Western Ontario McMaster Universities Osteoarthritis Inventory (WOMAC) in adult X-linked hypophosphatemia (XLH)","volume":"22","author":"Skrinar","year":"2019","journal-title":"Value Health"},{"issue":"1","key":"2026101614021659300_ref37","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/ckj\/sfab158","article-title":"An introduction to inverse probability of treatment weighting in observational research","volume":"15","author":"Chesnaye","year":"2022","journal-title":"Clin Kidney J"},{"issue":"4","key":"2026101614021659300_ref38","doi-asserted-by":"publisher","first-page":"101","DOI":"10.37737\/ace.22013","article-title":"Theory and practice of propensity score analysis","volume":"4","author":"Hashimoto","year":"2022","journal-title":"Ann Clin Epidemiol"},{"issue":"1","key":"2026101614021659300_ref39","doi-asserted-by":"publisher","first-page":"16","DOI":"10.21037\/atm.2018.12.10","article-title":"Balance diagnostics after propensity score matching","volume":"7","author":"Zhang","year":"2019","journal-title":"Ann Transl Med"},{"issue":"1","key":"2026101614021659300_ref40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1214\/09-STS313","article-title":"Matching methods for causal inference: a review and a look forward","volume":"25","author":"Stuart","year":"2010","journal-title":"Stat Sci"},{"issue":"8","key":"2026101614021659300_ref41","doi-asserted-by":"publisher","first-page":"S84","DOI":"10.1016\/j.jclinepi.2013.01.013","article-title":"Prognostic score-based balance measures can be a useful diagnostic for propensity score methods in comparative effectiveness research","volume":"66","author":"Stuart","year":"2013","journal-title":"J Clin Epidemiol"},{"issue":"9","key":"2026101614021659300_ref42","doi-asserted-by":"publisher","first-page":"603","DOI":"10.2217\/cer-2020-0013","article-title":"Propensity score matching and inverse probability of treatment weighting to address confounding by indication in comparative effectiveness research of oral anticoagulants","volume":"9","author":"Allan","year":"2020","journal-title":"J Comp Eff Res"},{"issue":"6","key":"2026101614021659300_ref43","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1093\/ecco-jcc\/jjad203","article-title":"Biologic therapy for inflammatory bowel disease: real-world comparative effectiveness and impact of drug sequencing in 13 222 patients within the UK IBD BioResource","volume":"18","author":"Kapizioni","year":"2024","journal-title":"J Crohns Colitis"},{"issue":"10","key":"2026101614021659300_ref44","doi-asserted-by":"publisher","first-page":"e10793","DOI":"10.1002\/jbm4.10793","article-title":"Cardiovascular safety in postmenopausal women and men with osteoporosis treated with denosumab and zoledronic acid: a post-authorization safety study","volume":"7","author":"Spangler","year":"2023","journal-title":"JBMR Plus"},{"issue":"1","key":"2026101614021659300_ref45","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1210\/clinem\/dgac518","article-title":"Long-term burosumab administration is safe and effective in adults with X-linked hypophosphatemia","volume":"108","author":"Weber","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026101614021659300_ref46","doi-asserted-by":"publisher","first-page":"F1170","DOI":"10.1152\/ajprenal.00072.2005","article-title":"\"Phosphatonins\" and the regulation of phosphorus homeostasis","volume":"289","author":"Berndt","year":"2005","journal-title":"Am J Physiol Renal Physiol"},{"key":"2026101614021659300_ref47","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/bonekey.2013.231","article-title":"Phosphate metabolism and vitamin D","volume":"3","author":"Fukumoto","year":"2014","journal-title":"Bonekey Rep"},{"issue":"1","key":"2026101614021659300_ref48","doi-asserted-by":"publisher","first-page":"10165","DOI":"10.1038\/s41598-021-89442-7","article-title":"Distribution of estimated glomerular filtration rate and determinants of its age dependent loss in a German population-based study","volume":"11","author":"Waas","year":"2021","journal-title":"Sci Rep"},{"issue":"5","key":"2026101614021659300_ref49","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1002\/cpt.3406","article-title":"Item response theory quantifies the relationship between improvements in serum phosphate and patient-reported outcomes in adults with X-linked hypophosphatemia","volume":"116","author":"Mehta","year":"2024","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"2026101614021659300_ref50","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s40272-020-00381-8","article-title":"New developments in the treatment of X-linked hypophosphataemia: implications for clinical management","volume":"22","author":"Saraff","year":"2020","journal-title":"Paediatr Drugs"},{"issue":"8","key":"2026101614021659300_ref51","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1507\/endocrj.EJ22-0239","article-title":"Advances in understanding of phosphate homeostasis and related disorders","volume":"69","author":"Michigami","year":"2022","journal-title":"Endocr J"},{"issue":"4","key":"2026101614021659300_ref52","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1172\/JCI72829","article-title":"Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia","volume":"124","author":"Carpenter","year":"2014","journal-title":"J Clin Invest"},{"issue":"10","key":"2026101614021659300_ref53","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1056\/NEJM197209072871003","article-title":"Use of phosphate and vitamin D to prevent dwarfism and rickets in X-linked hypophosphatemia","volume":"287","author":"Glorieux","year":"1972","journal-title":"N Engl J Med"},{"key":"2026101614021659300_ref54","doi-asserted-by":"publisher","first-page":"1702656","DOI":"10.3389\/fendo.2025.1702656","article-title":"Biochemical evaluation of X-linked hypophosphatemia and tumor-induced osteomalacia: insights into diagnosis and management","volume":"16","author":"Diaz-Garzon Marco","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026101614021659300_ref55","article-title":"Burosumab for treating X-linked hypophosphataemia in adults","author":"National Institute for Health and Care Excellence (NICE)","year":"2024","journal-title":"Technology Appraisal Guidance TA993"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmr\/advance-article-pdf\/doi\/10.1093\/jbmr\/zjag136\/71354799\/zjag136.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/advance-article-pdf\/doi\/10.1093\/jbmr\/zjag136\/71354799\/zjag136.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:02:24Z","timestamp":1792173744000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/advance-article\/doi\/10.1093\/jbmr\/zjag136\/8832431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":55,"URL":"https:\/\/doi.org\/10.1093\/jbmr\/zjag136","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"article-number":"zjag136"}}